{"schema_version":"secwatch.filing_event.v1","accession":"0001609550-22-000047","form_type":"8-K","ticker":"INSP","cik":"0001609550","company_name":"Inspire Medical Systems, Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.393283+00:00","generated_at":"2026-06-22T18:28:56.768805+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inspire Medical Q3 revenue $109.2M (+77% YoY); raises FY2022 guidance to $384-388M","bullets":["Revenue $109.2M (+77% YoY); raised FY2022 guidance to $384-388M from $354-362M.","Gross margin 81.9% (down from 86.0%) on inventory obsolescence and inflation; FY margin guidance maintained at 83-85%.","Net loss $16.8M ($0.60 diluted EPS) vs $10.3M ($0.38); cash $427.5M after $243.8M public offering.","Added 59 new U.S. centers (total 844) and 18 sales territories (total 209); launched Bluetooth remote and silicone leads.","European revenue down 14% on FX; France final pricing secured, reimbursement expected early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001609550-22-000047","json":"https://secwatch.observer/filing/0001609550-22-000047.json","markdown":"https://secwatch.observer/filing/0001609550-22-000047.md","text":"https://secwatch.observer/filing/0001609550-22-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609550/000160955022000047/0001609550-22-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609550/000160955022000047/insp-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T18:28:56.768805+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa849da8854c087fe9c83322b899f63afee6c761","claim":"Inspire Medical Systems, Inc. reported quarter ended September 30, 2022 results: revenue $109.2 million. Guidance raised.","evidence_excerpt":"solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended September 30, 2022. Recent Business Highlights • Generated revenue of $109.2 million in the third quarter of 2022, a 77% increase over the same quarter last year • Achieved gross margin of 81.9% in the third quarter of 2022 • Activated 59 new centers in the U.S.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609550/000160955022000047/0001609550-22-000047-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Revenue","value":"$109.2 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}